Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 plus enlonstobart injection with or without chemotherapy in advanced EGFR/ALK wild-type NSCLC and other advanced solid tumors
CTR20243338Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CPO301, PBI-1308 in non-small cell lung cancer (NSCLC), Nonhematologic neoplasms, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Sep 2024; status: active.
02
Drugs
CPO301PBI-1308
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243338.